N-α-Fmoc-N-δ-trityl-D-glutamine

N-α-Fmoc-N-δ-trityl-D-glutamine is a protected D-glutamine derivative engineered for solid-phase peptide synthesis, featuring an Fmoc-protected α-amino group and a δ-N-trityl protection on the side-chain amide. The molecule contains a stereodefined D-glutamine backbone with a chiral center at the α-carbon, an activated carboxyl functionality suitable for peptide coupling after conversion to the appropriate reactive form, and two orthogonally removable protecting groups that control chemoselectivity during stepwise assembly. The trityl group on the side-chain amide suppresses undesired side reactions and preserves the glutamine side chain for later deprotection and downstream derivatization, while the Fmoc group enables iterative N-terminal deprotection cycles under standard peptide chemistry conditions. The combination of aromatic protecting groups and the glutamine amide side chain gives a predictable reactivity profile for peptide bond formation and for controlled functional-group transformations after synthesis.

1. Peptide Synthesis

N-α-Fmoc-N-δ-trityl-D-glutamine supports peptide building-block workflows in peptide synthesis by providing an Fmoc-protected α-amino group for N-to-C coupling sequences and a trityl-protected δ-amide to prevent premature side-chain participation. The glutamine side-chain amide, held in a protected state, can be incorporated into peptides and then revealed through orthogonal deprotection strategies to generate a defined glutamine residue for subsequent labeling, cyclization, or conjugation chemistry. The D-configuration at the α-stereocenter enables stereochemically defined incorporation of D-glutamine into peptide analogs, which can be relevant for conformational control and protease resistance studies. The protected amide functionality also allows downstream conversion into other glutamine-derived motifs while maintaining compatibility with standard peptide coupling and purification pipelines.

2. Bioconjugation Chemistry

N-α-Fmoc-N-δ-trityl-D-glutamine is suitable for bioconjugation reagent development when the protected side-chain amide is used as a controlled handle for post-synthetic modification. The orthogonal protection pattern allows peptide or linker constructs to be assembled with the glutamine side chain masked, then deprotected to expose the δ-amide for targeted derivatization routes such as electrophile-mediated functionalization or conversion into reactive intermediates used in conjugate assembly. The stereodefined D-glutamine residue can influence local hydrogen-bonding and spacing within conjugates, supporting design of molecular scaffolds for chemical biology and biomolecule labeling. The compound's protected architecture therefore serves as a practical intermediate for generating glutamine-functionalized peptide conjugates and related biomolecular constructs.

3. Chemical Biology Probes

N-α-Fmoc-N-δ-trityl-D-glutamine can be applied in chemical biology probe construction where glutamine side-chain functionality is required for molecular recognition or for installing reporter groups. The Fmoc strategy supports building peptide-based probes with controlled N-terminal identity, while the trityl-protected δ-amide enables selective unveiling of the side chain at a chosen stage to support probe maturation. The D-glutamine stereochemistry can be leveraged to tune peptide conformation and stability in assay-relevant settings, including studies that compare L- versus D-amino acid incorporation effects on binding or processing. The resulting glutamine-bearing peptide or peptidomimetic derivatives can be used as research intermediates for mechanistic probes, substrate analogs, and structure-guided chemical biology experiments.

4. Peptidomimetics And SAR Studies

N-α-Fmoc-N-δ-trityl-D-glutamine serves as a chiral building block for peptidomimetic construction in structure-activity relationship studies that require glutamine-like side-chain presentation. The protected amide side chain supports the synthesis of analogs where the δ-N functionality is retained for later transformation into constrained, cyclized, or substituted motifs that mimic glutamine interactions. The orthogonality between Fmoc and trityl protection enables systematic variation of peptide length, N-terminal modifications, and side-chain chemistry without cross-reactivity, supporting iterative SAR workflows. The stereodefined D-glutamine incorporation enables direct evaluation of stereochemical effects on binding geometry and hydrogen-bonding networks within peptide-mimetic scaffolds.

5. Pharmaceutical Intermediate Preparation

N-α-Fmoc-N-δ-trityl-D-glutamine is relevant to pharmaceutical intermediate preparation and process chemistry for producing protected amino acid inputs used in the manufacture of peptide-based intermediates and analog libraries. The compound's dual protection pattern provides a controlled, isolable form of a glutamine residue that can be incorporated into larger protected peptide fragments, with the Fmoc group enabling stepwise N-terminal assembly and the trityl group maintaining the side-chain amide in a non-reactive state during coupling sequences. The chiral D-center and protected functional groups support reproducible stereochemical outcomes across synthetic batches, which is important for downstream conversion to deprotected peptide intermediates. The resulting peptide fragments and glutamine-containing intermediates can be further processed into drug-discovery tool compounds, process-scale peptide building blocks, and fine chemical outputs requiring consistent amino acid stereochemistry and chemoselective deprotection behavior.

1. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

2. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

3. Crystal Structure of BamB from Pseudomonas aeruginosa and Functional Evaluation of Its Conserved Structural Features

4. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

5. Implications of ligand-receptor binding kinetics on GLP-1R signalling